Personal information

No personal information available

Activities

Collapse all

Professional activities (1)

Faculty Opinions: London, GB

2008-03-28 to present | Faculty Member
Invited position
Source: check_circle
Faculty Opinions

Works (46)

Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board

Cancer
2024-12 | Journal article
DOI: 10.1002/cncr.35537
Contributors: Ajay Gupta; Matthew S. Dietz; Richard F. Riedel; Aditi Dhir; Scott C. Borinstein; Michael S. Isakoff; Jamie M. Aye; Nino Rainusso; Amy E. Armstrong; Steven G. DuBois et al.
Source: check_circle
Crossref

Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statement

Cancer Treatment Reviews
2024-12 | Journal article
DOI: 10.1016/j.ctrv.2024.102846
Contributors: Candace L. Haddox; Jason L. Hornick; Christina L. Roland; Elizabeth H. Baldini; Vicki L. Keedy; Richard F. Riedel
Source: check_circle
Crossref

Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities

The Oncologist
2024-12-06 | Journal article
DOI: 10.1093/oncolo/oyae218
Contributors: Laura H Rosenberger; Richard F Riedel; Emilia J Diego; Amanda L Nash; Juneko E Grilley-Olson; Natalie A Danziger; Ethan S Sokol; Jeffrey S Ross; Sarah L Sammons
Source: check_circle
Crossref

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma

Journal of Clinical Oncology
2024-11 | Journal article
DOI: 10.1200/JCO.24.00020
Contributors: Paul A. Meyers; Noah Federman; Najat Daw; Peter. M. Anderson; Lara E. Davis; AeRang Kim; Margaret E. Macy; Angela Pietrofeso; Ravin Ratan; Richard F. Riedel et al.
Source: check_circle
Crossref

Kaposi Sarcoma of the Cardiac Allograft in a Heart Transplant Recipient

Annals of Internal Medicine: Clinical Cases
2024-11-01 | Journal article
DOI: 10.7326/aimcc.2024.0435
Contributors: Eric A. Wilson; Carolyn Glass; Danielle Elliott Range; Julie M. Steinbrink; Cameron R. Wolfe; Richard F. Riedel; Adam DeVore; Madeleine R. Heldman
Source: check_circle
Crossref

Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study

Cancer
2024-08-15 | Journal article
DOI: 10.1002/cncr.35324
Contributors: Elizabeth T. Loggers; Rashmi Chugh; Noah Federman; Lee Hartner; Richard F. Riedel; Sunny Cho; David Hyslop; Allison Lim; Ana B. Oton; Kutluk H. Oktay
Source: check_circle
Crossref

Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Journal of Clinical Oncology
2024-05-01 | Journal article
DOI: 10.1200/JCO.23.02266
Contributors: Andrew J. Wagner; Vinod Ravi; Richard F. Riedel; Kristen Ganjoo; Brian A. Van Tine; Rashmi Chugh; Lee Cranmer; Erlinda M. Gordon; Jason L. Hornick; Heng Du et al.
Source: check_circle
Crossref

Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board

Cancer
2023-11 | Journal article
DOI: 10.1002/cncr.34942
Contributors: Ajay Gupta; Richard F. Riedel; Chirag Shah; Scott C. Borinstein; Michael S. Isakoff; Rashmi Chugh; Jeremy M. Rosenblum; Erin S. Murphy; Shauna R. Campbell; Catherine M. Albert et al.
Source: check_circle
Crossref

Hydropneumodissection-Assisted Cryoablation of Recurrent Sarcoma Adjacent to the Sciatic Nerve as a Limb-Sparing Alternative to Hindquarter Amputation

Journal of Vascular and Interventional Radiology
2023-05 | Journal article
DOI: 10.1016/j.jvir.2022.12.469
Contributors: Alan A. Sag; Richard F. Riedel; William C. Eward; Julia D. Visgauss; Brian E. Brigman
Source: check_circle
Crossref

Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6529322
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6529322.v1
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Data from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528611
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Data from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528611.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Figure S1 from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22476191
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Figure S1 from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22476191.v1
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Figure S2 from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22476188
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Figure S2 from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22476188.v1
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Supplemental Legend from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473821
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplemental Legend from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473821.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22476185
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Supplementary Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22476185.v1
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Supplementary Figure 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473818
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473818.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473815
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473815.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 2 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473812
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 2 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473812.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 3 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473806
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 3 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473806.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 4 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473803
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 4 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473803.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 5 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473800
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 5 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473800.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 6 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473797
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 6 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473797.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 7 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473794
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Supplementary Table 7 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22473794.v1
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma

The Oncologist
2022-10-01 | Journal article
DOI: 10.1093/oncolo/oyac155
Contributors: Richard F Riedel; Victoria Chua; Ania Moradkhani; Natalie Krkyan; Amir Ahari; Atsushi Osada; Sant P Chawla
Source: check_circle
Crossref

Evolving strategies for management of desmoid tumor

Cancer
2022-08-15 | Journal article
DOI: 10.1002/cncr.34332
Contributors: Richard F. Riedel; Mark Agulnik
Source: check_circle
Crossref

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1

Journal of Clinical Oncology
2022-04-20 | Journal article
DOI: 10.1200/JCO.20.03452
Contributors: Sant P. Chawla; Brian A. Van Tine; Seth M. Pollack; Kristen N. Ganjoo; Anthony D. Elias; Richard F. Riedel; Steven Attia; Edwin Choy; Scott H. Okuno; Mark Agulnik et al.
Source: check_circle
Crossref

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Journal of Clinical Oncology
2021-11-20 | Journal article
DOI: 10.1200/JCO.21.01728
Contributors: Andrew J. Wagner; Vinod Ravi; Richard F. Riedel; Kristen Ganjoo; Brian A. Van Tine; Rashmi Chugh; Lee Cranmer; Erlinda M. Gordon; Jason L. Hornick; Heng Du et al.
Source: check_circle
Crossref

A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study

The Oncologist
2020-11-20 | Journal article
DOI: 10.1634/theoncologist.2020-0679
Contributors: Richard F. Riedel; Karla V. Ballman; Yao Lu; Steven Attia; Elizabeth T. Loggers; Kristen N. Ganjoo; Michael B. Livingston; Warren Chow; Jennifer Wright; John H. Ward et al.
Source: check_circle
Crossref

A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

Clinical Cancer Research
2020-08-15 | Journal article
DOI: 10.1158/1078-0432.CCR-20-0591
Contributors: Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Source: check_circle
Crossref

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

Clinical Cancer Research
2020-03-15 | Journal article
DOI: 10.1158/1078-0432.CCR-19-1824
Contributors: Emily Z. Keung; Melissa Burgess; Ruth Salazar; Edwin R. Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A. Van Tine; Scott M. Schuetze; Steven Attia; Richard F. Riedel et al.
Source: check_circle
Crossref

Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review

Cancers
2018-11 | Journal article | Author
DOI: 10.3390/cancers10110417
Contributors: Richard F. Riedel; Robin L. Jones; Antoine Italiano; Chet Bohac; Juliette Thompson; Kerstin Mueller; Zaeem Khan; Seth M. Pollack; Brian A. Van Tine
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas [version 1; referees: 2 approved]

2018-11-02 | Journal article
DOI: 10.12688/f1000research.15868.1
Part of ISSN: 2046-1402
Contributors: Jennifer Choe; Richard Riedel
Source: check_circle
F1000
grade
Preferred source (of 2)‎

Peer review (9 reviews for 4 publications/grants)

Review activity for British journal of cancer. (1)
Review activity for Faculty Opinions (2)
Review activity for npj precision oncology. (1)
Review activity for Targeted oncology. (5)
How many people are using ORCID?